MDT-AP-1207
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 72.96000000000001
- os_event
- false
- age_years
- 5
- sex
- M
- new_clusters
- C3
- umap1_2d
- 6.613145202
- umap2_2d
- 3.940034993
- umap1_3d
- 3.321638374
- umap2_3d
- -2.458427639
- umap3_3d
- -2.575408759
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.420
- NOTCH_SIGNALING+0.240
- HEME_METABOLISM+0.150
- DNA_REPAIR+0.130
- APICAL_JUNCTION+0.120
- UNFOLDED_PROTEIN_RESPONSE+0.120
- MYC_TARGETS_V2+0.100
- HEDGEHOG_SIGNALING+0.090
- MITOTIC_SPINDLE+0.090
- PEROXISOME+0.070
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- INTERFERON_ALPHA_RESPONSE-0.410
- ALLOGRAFT_REJECTION-0.400
- E2F_TARGETS-0.390
- INFLAMMATORY_RESPONSE-0.390
- INTERFERON_GAMMA_RESPONSE-0.390
- COMPLEMENT-0.360
- KRAS_SIGNALING_UP-0.350
- APOPTOSIS-0.320
- G2M_CHECKPOINT-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1357 | Med | Medulloblastoma | 0.910 |
| 2 | MDT-AP-0038 | Med | Medulloblastoma | 0.882 |
| 3 | MDT-AP-0578 | Med | Medulloblastoma | 0.877 |
| 4 | MDT-AP-1134 | Med | Medulloblastoma | 0.873 |
| 5 | MDT-AP-0402 | Med | Medulloblastoma | 0.867 |
| 6 | MDT-AP-1341 | Med | Medulloblastoma | 0.852 |
| 7 | MDT-AP-0819 | Med | Medulloblastoma | 0.851 |
| 8 | ERR2208948 | — | — | 0.850 |
| 9 | MDT-AP-1120 | Med | Medulloblastoma | 0.849 |
| 10 | MDT-AP-0550 | Med | Medulloblastoma | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.420 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.060 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |